GLP-1 & compounded medication availability in Pennsylvania (2026)

Pennsylvania runs one of the more procedural pharmacy frameworks in the country: out-of-state pharmacies register with the state board on a biennial cycle, keep a toll-free line staffed for Pennsylvania patients, and follow the Pharmacy Act’s compounding provisions, and in 2024 the state finally put a telemedicine framework into law. None of it names any of the ten lines on this page. What follows is the researched Pennsylvania picture: what ships, what does not, and the state’s own sources for the rules in between.

Baseline state

Availability facts last reviewed: November 16, 2026

What ships to Pennsylvania: all ten lines

Availability of all ten OrderlyMeds product lines in Pennsylvania, with typical delivery times and notes
Product lineAvailable in Pennsylvania?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Filled on patient-specific prescriptions by partner pharmacies holding Pennsylvania’s nonresident registration.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same registration basis as the semaglutide row; flat national pricing.
NAD+ Yes 8–10 business days Ships from licensed partner pharmacies registered for Pennsylvania.
Sermorelin Yes 8–10 business days Longevity family; the ordering flow is the same everywhere.
Glutathione No N/A Not in the OrderlyMeds formulary today.
BPC-157 Yes 8–10 business days Compounded injectable. Federal record in its section below.
TB-500 Yes 8–10 business days Compounded injectable; its own section follows.
KPV No N/A Not carried in any state; our peptide lines are injectables only.
Epitalon Yes 8–10 business days Compounded injectable; federal standing below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record is its own, below.

Ten lines tracked, ten lines shown, including the two we do not ship. Pennsylvania facts were last reviewed on November 16, 2026.

Research peptides in Pennsylvania: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Pennsylvania’s answer on these five lines is the catalog answer, because the state adds no peptide-specific layer of its own: BPC-157, TB-500, Epitalon and MOTS-c ship to Pennsylvania as compounded injectables on patient-specific prescriptions, and KPV does not ship anywhere, since we compound these lines as injectables only. What varies between the five is the federal record. Each section below states its line’s own, in full, whether or not that line is available to you.

BPC-157 in Pennsylvania

Pennsylvania orders for BPC-157 are filled as compounded injectables on patient-specific prescriptions. The two federal facts below apply in full.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Pennsylvania

TB-500 is dispensed to Pennsylvania addresses as a compounded injectable under a patient-specific prescription. Its federal record follows.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Pennsylvania

We do not ship KPV to Pennsylvania, or to any state. Our peptide lines are compounded as injectables, and KPV is not carried in that form.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Pennsylvania

Epitalon ships to Pennsylvania as a compounded injectable on a patient-specific prescription. Its federal standing is stated below.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Pennsylvania

MOTS-c reaches Pennsylvania addresses as a compounded injectable on a patient-specific prescription. Its federal record is not interchangeable with the four above, and is stated below as its own.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Pennsylvania’s pharmacy regulators say about compounded medications

Pennsylvania’s state board publishes its requirements through the Pharmacy Act and its regulations, and the piece that matters most for a telehealth patient is the registration requirement on out-of-state pharmacies. The board has published nothing specific to GLP-1s or peptides; the state’s 2024 telemedicine law is the other recent change worth knowing about.

Pennsylvania regulates pharmacy practice and compounding under the Pharmacy Act (Act 699 of 1961, as amended) and State Board of Pharmacy regulations; no GLP-1-specific or peptide-specific prohibition has been published by the board. Source: Pennsylvania State Board of Pharmacy.

A nonresident pharmacy may not ship, mail or deliver prescription drugs to Pennsylvania patients unless the State Board of Pharmacy has issued it a certificate of registration; registrations renew biennially, and registrants must maintain a toll-free telephone line for Pennsylvania patients during regular hours. Source: Pennsylvania State Board of Pharmacy.

Pennsylvania enacted a statewide telemedicine framework in 2024 (Act 42), and permits prescribing on the basis of a telehealth encounter that meets the standard of care. Source: Center for Connected Health Policy (CCHP) Policy Finder.

For a Pennsylvania patient the upshot is procedural rather than restrictive: the pharmacy filling your prescription must hold a Pennsylvania registration and be reachable on a toll-free line, and your prescription must come from a real evaluation, which is how every OrderlyMeds order works, through a Pennsylvania-licensed provider, at the national price published on our pricing page.

Pennsylvania availability FAQs

Is compounded semaglutide available in Pennsylvania?

Yes. OrderlyMeds ships compounded semaglutide to Pennsylvania addresses on patient-specific prescriptions, through partner pharmacies registered with the state board. New customers start at $74/month for the first two months.

Do I need to see a doctor in person to get started in Pennsylvania?

No. Pennsylvania’s 2024 telemedicine law put telehealth care on a statutory footing, and an evaluation by a Pennsylvania-licensed provider over telehealth is how every OrderlyMeds order begins.

Can I get BPC-157 or other research peptides shipped to Pennsylvania?

Four of the five: BPC-157, TB-500, Epitalon and MOTS-c ship to Pennsylvania as compounded injectables on patient-specific prescriptions. KPV does not, because we compound these lines as injectables only. Each section above carries that line’s own federal record, which applies no matter where you buy.

How long does delivery to Pennsylvania take?

Our published window is 8–10 business days from signup.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone